Continuum Advisory, LLC Biocryst Pharmaceuticals Inc Transaction History
Continuum Advisory, LLC
- $727 Million
- Q1 2025
A detailed history of Continuum Advisory, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Continuum Advisory, LLC holds 1,668 shares of BCRX stock, worth $13,494. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,668
Previous 1,198
39.23%
Holding current value
$13,494
Previous $9,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding BCRX
# of Institutions
294Shares Held
181MCall Options Held
721KPut Options Held
489K-
Vanguard Group Inc Valley Forge, PA21.7MShares$175 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$161 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.93MShares$72.2 Million5.64% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.7MShares$70.4 Million1.06% of portfolio
-
State Street Corp Boston, MA7.81MShares$63.2 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.5B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...